LegalMay 29, 2026, 05:17 PM
Cardiff Oncology disputes NMS termination of License Agreement
AI Summary
Cardiff Oncology, Inc. is embroiled in a legal dispute with Nerviano Medical Sciences S.r.l. (NMS) regarding their License Agreement. Cardiff previously filed a lawsuit seeking to compel NMS to continue performance and a declaratory judgment that Cardiff did not breach the agreement. NMS subsequently informed Cardiff of its termination of the agreement, citing alleged material breaches related to patent inventorship and failure to use commercially reasonable efforts for onvansertib development. Cardiff has rejected NMS's termination notice, asserting it is legally ineffective and factually unsupported, and plans to continue performing under the agreement.
Key Highlights
- Cardiff Oncology filed a lawsuit against Nerviano Medical Sciences S.r.l. (NMS) on May 19, 2026, disputing NMS's breach allegations.
- The lawsuit seeks injunctive relief for NMS to continue performing and a declaratory judgment that Cardiff did not breach the Agreement.
- NMS informed Cardiff on May 27, 2026, of its termination of the License Agreement dated March 13, 2017.
- NMS alleges Cardiff materially breached by declining to name Dr. Barbara Valsasina as a joint inventor of U.S. Pat. Nos. 12,144,813 and 12,263,173.
- NMS also alleges Cardiff failed to use Commercially Reasonable Efforts for onvansertib development and regulatory approvals.
- Cardiff promptly responded that NMS's termination notice is legally ineffective, factually unsupported, and procedurally improper.
- Cardiff stated it will continue to perform under the Agreement despite NMS's termination notice.
Price Impact
More from CRDF